Stuart Therapeutics adds recognized leaders in the development, commercialization of ophthalmic therapies.
Stewart, Florida., December 22, 2024 /PRNewswire/ — Stuart Therapeutics today announced the appointment Trace values and: Jason Werner to the company’s board of directors, bringing the total number of board members to five. These new directors will fill the positions previously held Robert O. BarattaMD, who died suddenly in the third quarter of this year and retired US representative. Diane Black, RNwho recently resigned as a member of the company’s board.
Trace values is a strategic business consultant and owner ™ V Associates LLC because July 2019. Mrs. Valorie has 30 years of experience in the pharmaceutical and biotech industry. Mrs. Valorie worked as Senior Vice President, General Manager USA: pharmaceutical and surgical businesses at Bausch + Lomb July 2012 to: May 2019. Before joining B+L in 2012 Mrs. Valory served as Commercial Head of Ophthalmology Pfizer: Inc. (NYSE: NYSE:) where he had global responsibility for ophthalmic brands as well as mid-stage portfolio commercial development and long-term strategic planning Board member. Glaucoma Research Foundation Directors (GRF). Mrs. Valorie has a master’s degree in business administration Rensselaer Polytechnic Institute and a Bachelor of Science in Molecular Biology University of Connecticut time Storrs, CT.
Jason Werner Currently serves as the Executive Chairman of Sightstream Biotherapeutics, a biotechnology company focused on the development of regenerative therapies in ophthalmology, and is a member of the Board of Directors of InflammX Therapeutics. Mr. Werner he served as a director of Alimera (NASDAQ:) from Q2 2023 until joining Alimera’s management team in Q4 2023 and then helped lead the company’s recent sale to ANI Pharma from Q4-2024. Mr. Werner formerly co-founder and chief operating officer Eevance Pharmaceuticals from the establishment of the company to its sale to Santen Pharmaceuticals Ltd. He has also held a number of commercial development roles and corporate strategy positions at companies such as Sun Pharma, Nickox (EPA:) SA and: Inspire Pharmaceuticalsall this in the field of ophthalmology. Mr. Werner received a bachelor’s degree in business administration University of New Hampshire.
“We are excited to bring Tracy and Jason as members of our Board of Directors and senior advisors to Stuart Therapeutics as we move into our next phase of development and commercialization of ophthalmic therapies,” said Eric Smurf, Stewart’s President and CEO. “Our team will benefit from the successful experience they bring to our organization. We also want to appreciate the contributions of our friend and co-founder Bob BarattaMD, and: Diane Black, RNwho were instrumental in guiding the company through its formative stages and we wish Diana every success in her future endeavours.”
“I am excited to join the board of Stuart Therapeutics. It is truly exciting to be at the forefront of such an innovative biotech company. I look forward to working with the incredible team that is helping to lead the company to make a significant impact in ophthalmology.” on the lives of diagnosed patients,” he said. Tracy Valory.
Jason Werner “This is an exciting time for Stuart Therapeutics with key development and pipeline milestones on the horizon. I look forward to working alongside Tracy and Eric and the rest of the talented team to ensure these new therapeutics reach patients while maximizing them.” shareholder value Stuart: and its contributors”.
Near Stuart Therapeutics, Inc.
Stuart Therapeutics, Inc. is a clinical-stage ophthalmic therapeutic development company based in Stewart, Florida. The company’s lead asset, ST-100, is in the final stages of its Phase 3 clinical trial, with a readout expected in the first quarter of 2025. Stuart: He also develops leading edge programs in retinal disease and myopia and has a development partnership through a glaucoma neuroprotection license. Glaukos Corp (NYSE:). Aliso Viejo, California.
Media contact.
Eric Smurf
President and CEO
eric@stuarttherapeutics.com
206-228-2781
www.stuarttherapeutics.com
English